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Abstract Tumor hypoxia is a common determinant of
resistance to cytotoxic therapies and metastatic behavior.
In rectal cancer patients receiving preoperative chemo-
radiotherapy, tyrosine kinase activities in tumors with
poor and good treatment responses were found to differ.
Given that tyrosine kinase signaling mediates hypoxic
tissue adaptation, the present study examined whether
tumor kinase activity might also correlate with systemic
dissemination of rectal cancer. Immunomagnetic selec-
tion of disseminated tumor cells (DTC) from bone
marrow aspirates was undertaken in 55 patients with
locally advanced rectal cancer. Using peptide arrays with
144 tyrosine kinase substrates, phosphopeptide signatures
were generated from patients’ baseline tumor biopsies, to
study association between DTC and tumor tyrosine
kinase activity regulated ex vivo by sunitinib. Dissemi-
nated tumor cells were detected in 60% of cases, and
these patients had signiﬁcantly poorer metastasis-free
survival than patients without DTC. Phosphorylation of
31 array tyrosine kinase substrates by tumor samples was
signiﬁcantly more strongly inhibited by sunitinib in the
DTC-negative patients, with a number of phosphosub-
strates representing angiogenic factors. In this cohort of
rectal cancer patients, tumor phenotypes deﬁned by a
subset of tyrosine kinase activities correlating with weak
ex vivo inhibition by sunitinib, was associated with early
systemic dissemination.
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Introduction
In order to cure rectal cancer, two therapeutic challenges
must be met, namely eradication of tumor within the pelvic
cavity and secondly, the prevention of systemic tumor
dissemination. The natural disease course of rectal cancer
makes it an ideal model system to explore the possible role
of tumor hypoxia in therapy resistance and development of
metastasis. Tissue hypoxia is deﬁned by reduced oxygen
levels, typically 2% oxygen or less, and occurs in a wide
range of pathological conditions [1, 2]. Within classical
radiobiology, hypoxia is recognized as a main mechanism
involved in tumor resistance to radiation [3, 4]. Moreover,
recent research supports the hypothesis that tumor hypoxia
is one of the major driving forces of the metastatic process
[5]. Adaptive cellular responses to hypoxia allow for pro-
cesses such as proliferation, migration, and in particular
angiogenesis, and involve activation of a range of kinase
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receptor tyrosine kinases PDGFR, VEGFR, and EPOR [1,
5, 6].
Locally advanced rectal cancer (LARC) comprises pri-
mary tumors that grow beyond the rectal wall to an extent
that precludes primary surgical removal with adequate
microscopic margins. Hence, treatment of LARC is mul-
timodal, involving preoperative chemoradiotherapy aimed
at macroscopic downsizing and control of subclinical
tumor extension within the pelvic cavity, to enable com-
plete tumor removal by subsequent surgery. However, even
with successful local treatment, a substantial number of
patients will develop metastatic disease as result of early
undetected systemic dissemination of tumor cells [7]. The
phase II trial Locally Advanced Rectal Cancer—Radiation
Response Prediction (LARC-RRP), registered with Clini-
calTrials.gov number NCT00278694, was launched pri-
marily to identify predictive biomarkers of tumor radiation
sensitivity, and we have recently reported that this was
feasible by kinase activity proﬁling of baseline tumor
biopsies [8]. Using peptide arrays with tyrosine kinase
substrates, we found that phosphopeptide levels generated
by tumors with poor response to the preoperative chemo-
radiotherapy were signiﬁcantly higher than substrate
phosphorylation resulting from tumors with good treatment
response. The elevated kinase activity in poor-responding
tumors was suppressed by ex vivo addition of the tyrosine
kinase inhibitor sunitinib, and represented signaling
implicated in experimental radiation resistance.
Given that tyrosine kinase signaling is involved in
adaptive responses to tumor hypoxia, the present study
aimed to determine how tumor kinase activity might relate
to systemic disease dissemination. Hence, in the investi-
gation of the LARC-RPP study patients reported here, we
endeavored to correlate the individual patient’s tumor
tyrosine kinase activity to negative or positive status for
disseminated tumor cells (DTC) to bone marrow as the
clinical endpoint, using the presence of DTC as biomarker
of metastatic recurrence risk [9]. Immunomagnetic selec-
tion of DTC was performed at the time of diagnosis, and by
applying previously acquired ex vivo sunitinib inhibition
proﬁles from the baseline primary tumor biopsies [8], the
association between the tumor kinome and early systemic
dissemination in terms of DTC status was studied.
Patients and methods
Patients and procedures
The patient population reported here was enrolled between
October 2005 and December 2007. Patient eligibility cri-
teria and evaluation procedures have been described
previously [8]. Three patients with synchronous resectable
liver metastases were also included in this study. The
experimental treatment protocol, intended to intensify
preoperative therapy for LARC, consisted of two cycles of
neoadjuvant chemotherapy (the Nordic FLOX regimen:
oxaliplatin 85 mg/m
2 on day 1 and daily bolus ﬂuorouracil
500 mg/m
2 and folinic acid 100 mg on days 1 and 2 every
second week) followed by chemoradiotherapy. Radiation
was delivered in daily 2-Gy fractions 5 days per week over
a ﬁve-week period; the initial 23 fractions to the macro-
scopic tumor volume and area at risk, and the two ﬁnal
fractions restricted to the macroscopic tumor, as deter-
mined by computed tomography-based planning. During
the radiotherapy course, concomitant chemotherapy was
given as oxaliplatin 50 mg/m
2 once weekly and capecita-
bine 825 mg/m
2 twice daily on days of radiotherapy. Sur-
gery was planned 6–8 weeks after completion of the
preoperative treatment. In accordance with national
guidelines, the patients did not receive postoperative
therapy.
The resected primary tumor specimens were histologi-
cally evaluated for response to the preoperative treatment
according to standard criteria (ypTN) and histomorpho-
logic tumor regression grade (TRG), as previously detailed
[8]. Brieﬂy, tumor response was graded within one of ﬁve
TRG categories, spanning from the absence of residual
tumor cells in the resected specimen (pathologic complete
response; TRG 1) to the lack of morphologic signs of tissue
response to treatment (TRG 5) [10]. The review procedures
of patient follow-up included clinical examination, blood
tests, and computed tomography scanning of the chest,
abdomen, and pelvis, at three- and six-month intervals for
the ﬁrst and second year, respectively, and twelve months
thereafter. Locally recurrent or metastatic disease and
death of any cause were recorded. Thus, the study end-
points were histomorphologic tumor response to neoadju-
vant therapy, disease-free survival, and overall survival.
Follow-up data was obtained from the clinical database and
censored on April 6th, 2011. Valid observations of the
presence or absence of distant metastases or local recur-
rence required designated radiological examination and/or
bioptic veriﬁcation. The three patients with resectable liver
metastases at the time of diagnosis were excluded from
analysis of metastasis-free survival.
Study-speciﬁc procedures
At the time of diagnosis, baseline study-speciﬁc primary
tumor biopsies (snap-frozen in liquid nitrogen and stored at
-80C) and bone marrow (15–40 ml drawn from the
anterior iliac crests) were obtained from 71 patients under
heavy sedation. Of these, 16 patients were excluded from
the present study, as six patients had bone marrow samples
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123that contained too few mononuclear cells for immuno-
magnetic selection, and ten patients had tumor biopsy
specimens in which kinase activity proﬁling had not been
performed because the patients were either ineligible after
study registration (n = 3), had withdrawn consent (n = 1),
had unexpectedly died during the preoperative treatment
(n = 1), had developed metastatic disease progression
during preoperative treatment that precluded deﬁnitive
surgery (n = 1), had tumor cell content less than 20%
within the biopsy specimen (n = 2), or had a biopsy
specimen in which kinase activity analysis was missing of
unknown reasons (n = 2). Thus, tumor kinase activity
signatures based on previous array phosphosubstrate data
were successfully identiﬁed for 55 patients with known
DTC status, and this study population is present within the
current analyses.
The tumor biopsies were sectioned using a cryostat
microtome, and hematoxylin-eosin stained slides were
evaluated for tumor content. The average tumor cell content
in the biopsy specimens was 44%, and no difference was
found between patients positive and negative for DTC
(P[0.66; two-sample t-test). Each biopsy specimen was
aliquoted by cryostat sectioning into 10-lm slices, and total
tissue volume was calculated by multiplying the surface
area of the section with the number of sample sections.
Protein lysates were prepared by adding 36 ll lysis buffer
(M-PER Mammalian Extraction Reagent containing Halt
Phosphatase Inhibitor Cocktail and EDTA-free Halt Prote-
ase Inhibitor Cocktail; Pierce Biotechnology, Inc., Rock-
ford, IL) per mm
3 tissue, and following vortexing and
centrifugation, 5 ll of the supernatant was added to the
reaction mixture, which was composed of Abl Reaction
Buffer (50 mmol/l Tris–HCl pH 7.5, 10 mmol/l MgCl2,
1 mmol/l EGTA, 2 mmol/l dithiothreitol, 0.01% Brij 35;
New England BioLabs,Inc., Ipswich, MA), 1 mg/ml bovine
serum albumin, 100 lmol/l ATP, and 12.5 lg/ml of the
monoclonal, FITC-conjugated anti-phosphotyrosine anti-
body (Exalpha Biologicals, Inc., Maynard, MA) to a total
volume of 40 ll in each array. No signiﬁcant variation was
observed in protein concentration in the sample lysates.
Four technical replicates were analyzed from each patient
sample to generate basal phosphosubstrate data. On the
same array plate, using three technical replicates for each
condition, each sample was also incubated in the presence
of 2.5 lmol/l sunitinib (Axxora, Lausen, Switzerland).
For determination of DTC status, superparamagnetic
sheep-antimouse IgG particles (Dynabeads M450; Invit-
rogen–Life Technologies, Oslo, Norway) were conjugated
with the monoclonal antibody MOC-31 (IQ Products,
Groningen, The Netherlands), and for each study patient,
immunomagnetic selection of tumor cells in bone marrow
was undertaken as previously described [11]. Brieﬂy,
mononuclear cells were isolated from the bone marrow
aspirate and incubated with magnetic immunobeads with
conjugated antibody, or without antibody for negative
control, and subsequently exposed to a magnet ﬁeld to
separate bead-rosetting cells from unbound cells. A patient
sample was classiﬁed as positive for DTC if a minimum of
two cells rosetted at least ﬁve beads with the MOC-31
antibody and no rosetted cells were detected in the negative
control.
Data adaptation and statistical analyses
The array data is available in the ArrayExpress database
[12] by accession number E-TABM-913. The curated
sunitinib inhibition data set that had been calculated from
the signal intensity from each array peptide after back-
ground subtraction and used previously [8] was applied as
input for the current statistical analysis. The data was log-
transformed after handling a small number of negative data
points by subtracting the 1% percentile of the data and
subsequently setting all remaining data points with value
less than 1 to the value 1. For each peptide, the sunitinib-
induced log-fold change was calculated by subtracting the
log-transformed signal in the absence of sunitinib (control)
from that in the presence of this tyrosine kinase inhibitor.
Peptides with sample-averaged signal less than 2
10 in the
control condition were excluded, leaving 102 peptides
above this threshold. A two-sample t-test was performed to
test for different level of sunitinib inhibition in DTC-
positive and DTC-negative patients (Supplementary
Table 1). The sunitinib inhibition proﬁles were visualized
as data color maps, in which clustering of peptides and
samples was imposed by sorting the data according to the
value of the ﬁrst principal component (peptides) and the
value of the scores on the ﬁrst principal component (sam-
ples) of a principal component analysis, using samples as
observations and spots as variables. Distribution of value of
the score on the ﬁrst principal component was compared to
clinical parameters using correlation coefﬁcients for con-
tinuous variables and one-way ANOVA tests for categor-
ical data. Data processing and visualizations were
performed in Matlab R2010A including the statistics
toolbox (Mathworks, Natick, MA).
Disease-free and overall survival was estimated by the
Kaplan–Meier method. The log-rank test was used to
determine survival differences in DTC-positive and DTC-
negative patients. Survival was measured from the date of
bone marrow sampling to the date of recurrent disease
detection or death. Distribution of parameters between
different groups was compared using Pearson’s Chi-square
exact two-sided test for categorical data and two-sample t-
test for continuous variables. The data analysis was per-
formed using SPSS version 16.0 (SPSS Inc., Chicago, IL).
P values less than 0.05 were considered statistically
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123signiﬁcant. Pathway connectivity of peptides was deter-
mined using UniProtKB/SwissProt database [13] and lit-
erature search.
Results
Patients
Table 1 describes characteristics of the 55 patients, in
whom immunomagnetic selection of tumor cells in bone
marrow aspirates as well as tyrosine kinase activity
proﬁling of tumor biopsies at the time of study enrolment
were performed. In 60% of patients, a median tumor cell
count of 6 (range 2–150) was detected in the bone marrow
samples (DTC-positive patients). No differences were
found between DTC-positive and DTC-negative patients
regarding gender, age, radiological TNM stage at diagno-
sis, serum carcinoembryonic antigen levels or hemoglobin
count at the time of diagnosis, or histological ypTN stage
or histomorphologic TRG score of the surgical specimens.
Median follow-up was 42 months (range 7–65). Three
patients (one DTC-negative and two DTC-positive indi-
viduals) were noted to have locally recurrent disease.
Table 1 Patient characteristics
TNM tumor–node–metastasis,
yp histopathologic staging
following chemoradiotherapy,
TRG histomorphologic tumor
regression grade following
chemoradiotherapy, CEA
carcinoembryonic antigen
a Censored at a median period
of 42 months (range 7–65)
All patients (n = 55) DTC-negative
patients (n = 22)
DTC-positive
patients (n = 33)
TNM stage at diagnosis
T2 3 (5.5%) 2 (9.1%) 1 (3.0%)
T3 33 (60.0%) 14 (63.6%) 19 (57.6%)
T4 19 (34.5%) 6 (27.3%) 13 (39.4%)
N0 6 (10.9%) 2 (9.1%) 4 (12.1%)
N1 8 (14.5%) 3 (13.6%) 5 (15.2%)
N2 41 (74.5%) 17 (77.3%) 24 (72.3%)
M0 52 (94.5%) 21 (95.5%) 31 (93.9%)
M1 3 (5.5%) 1 (4.5%) 2 (6.1%)
TN stage after chemoradiotherapy
ypT0 12 (21.8%) 5 (22.7%) 7 (21.2%)
ypT1 8 (14.5%) 4 (18.2%) 4 (12.1%)
ypT2 13 (23.6%) 6 (27.3%) 7 (21.2%)
ypT3 14 (25.5%) 4 (18.2%) 10 (30.3%)
ypT4 8 (14.5%) 3 (13.6%) 5 (15.2%)
ypN0 43 (78.2%) 19 (86.4%) 24 (72.7%)
ypN1 9 (16.4%) 3 (13.6%) 6 (18.2%)
ypN2 3 (5.5%) 0 (0%) 3 (9.1%)
TRG
1–2, good responders 40 (72.7%) 16 (72.7%) 24 (72.7%)
3, intermediate responders 9 (16.4%) 5 (22.7%) 4 (12.1%)
4, poor responders 6 (10.9%) 1 (4.5%) 5 (15.2%)
CEA
\5 lg/l 33 (60.0%) 14 (63.6%) 19 (57.6%)
C5 lg/l 22 (40.0%) 8 (36.4%) 14 (42.4%)
Median hemoglobin count, g/dl (range) 13.9 (10.0–16.3) 14.0 (10.0–16.3) 13.9 (10.8–15.4)
Gender
Male 31 (56.4%) 13 (59.1%) 18 (54.5%)
Female 24 (43.6%) 9 (40.9%) 15 (45.5%)
Median age, years (range) 61 (31–73) 61 (38–73) 59 (31–73)
Follow-up results
a
Locally recurrent disease 3 (5.5%) 1 (4.5%) 2 (6.1%)
Metastatic disease 16 (29.1%) 2 (9.1%) 14 (42.4%)
Death 8 (14.5%) 2 (9.1%) 6 (18.2%)
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123Metastasis-free survival was assessed for 52 patients, as the
three patients with synchronous liver metastases at the time
of diagnosis were omitted from this analysis, with the
DTC-positive group demonstrating signiﬁcantly poorer
metastasis-free survival (61%) than the DTC-negative
group (95%; P = 0.007; Fig. 1). At the time of follow-up
data censoring, eight patients were reported as deceased;
the number of cases was not statistically different between
the two groups of patients with negative and positive DTC
status.
Tumor tyrosine kinase activities
Ex vivo sunitinib inhibition proﬁles were derived from 102
(of 144 on the array) peptide kinase substrates that had
signal intensities above the deﬁned threshold. In Fig. 2,
patients (horizontal axis) and peptides (vertical axis) were
sorted according to principal component analysis. No
correlation was observed between tumor kinase activity
inhibition and gender, age, diagnostic TNM stage, ypTN
stage, or serum carcinoembryonic antigen levels or
hemoglobin count. A borderline signiﬁcant association was
found between inhibition of the phosphosubstrates and
tumor response to preoperative treatment in terms of TRG
status (P = 0.049), with the poor responders exhibiting
strongest inhibition (Supplementary Fig. 1).
Based on the scores of the principal component analysis,
ex vivo sunitinib inhibition of tumor kinase activity in
DTC-negative patients was stronger than in patients with
positive DTC status (P = 0.042; Supplementary Fig. 2).
Of the 102 peptides constituting the tyrosine kinase
inhibition proﬁle, phosphorylation of 31 kinase substrates
was signiﬁcantly more strongly inhibited in the DTC-
negative patients than in the DTC-positive individuals
(Table 2). The 31 discriminating phosphopeptides repre-
sented proteins derived from signaling pathways impli-
cated in various cellular processes, such as proliferation,
angiogenesis, and invasion. Of these, 13 peptides, mainly
representing PDGFR, VEGFR, and EPOR, were proteins
involved in angiogenesis-related pathways. Within the
entire 102-peptide panel, 23 angiogenesis-related sub-
strates were identiﬁed (Fig. 3), and sunitinib inhibition of
these phosphosubstrates was stronger in patients with
negative DTC status than in DTC-positive patients
(P = 0.019; Supplementary Fig. 3). Additionally, a sig-
niﬁcantly larger portion of angiogenesis-related substrates
(13 peptides) appeared among the 31 phosphopeptides
discriminating DTC status than within the remaining group
of substrates (ten angiogenesis-related among a total of 71;
P = 0.002).
Discussion
In this cohort of 55 LARC patients, tumor kinase activity
signatures associated with early systemic dissemination
were identiﬁed. For 31 peptides on the tyrosine kinase
substrate array, ex vivo sunitinib inhibition of phos-
phorylation generated by tumor biopsy specimens was
signiﬁcantly stronger for DTC-negative patients than for
patients with tumor cells identiﬁed in bone marrow, as
assessed by immunomagnetic selection at the time of
diagnosis. Many of the discriminating peptide substrates
represented signaling pathways that are activated by
tissue hypoxia, such as signaling mediated by PDGFR,
VEGFR, and EPOR [1, 6]. Accordingly, tumor-generated
Fig. 1 Metastasis-free survival of 52 study patients with locally
advanced rectal cancer as function of negative or positive status for
disseminated tumor cells (DTC) to bone marrow at the time of
diagnosis
Fig. 2 Ex vivo sunitinib inhibition proﬁles from 102 kinase sub-
strates. Patient tumor samples along horizontal axis, annotated by
negative (-) or positive (?) status for disseminated tumor cells to
bone marrow, and phosphosubstrates along vertical axis. Red
corresponds to stronger and blue to weaker inhibition of substrate
phosphorylation. (Color ﬁgure online)
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123phosphorylation of 23 angiogenesis-related peptides was
weakly inhibited in DTC-positive patients, who had
signiﬁcantly poorer metastasis-free survival than patients
without evidence of early systemic tumor dissemination.
Various reports have demonstrated that the presence of
tumor cells in bone marrow is a prognostic biomarker
associated with metastatic recurrence [14], including in
colorectal cancer [9]. In this study, hypothesizing that
hypoxic tumor signaling mediates both radiation resistance
and metastatic progression in rectal cancer, and using
previously acquired data [8], we endeavored to correlate
the individual patient’s tumor tyrosine kinase activity to the
DTC status. In two previous works applying the array
technology with tyrosine kinase substrates, we were able to
calculate basal kinase activity data and correlate with the
biological parameters of interest [8, 15]. In the present
study, however, after normalization of basal phosphosub-
strate level read-outs, no difference was found among the
study patients when comparing those with and without
DTC (data not shown). Since a reasonable explanation
Table 2 Array phosphopeptides (generated by tumors from patients with and without disseminated tumor cells to bone marrow) with different
levels of ex vivo sunitinib inhibition (P\0.05), listed according to signaling pathway connectivity
Peptide substrate
a Position of peptide sequence
b Phosphorylation
b Common name
a
Angiogenesis
PDGFRB 1002–1014 Y1009 Beta platelet-derived growth factor receptor
PDGFRB 709–721 Y716 Beta platelet-derived growth factor receptor
PDGFRB 771–783 Y771, Y775, Y778 Beta platelet-derived growth factor receptor
PDGFRB 768–780 Y771, Y775, Y778 Beta platelet-derived growth factor receptor
PDGFRB 572–584 Y579, Y581 Beta platelet-derived growth factor receptor
FLT-1 (VEGFR1) 1326–1338 Y1327, Y1333 Vascular endothelial growth factor receptor 1
KDR (VEGFR2) 1168–1180 Y1175 Vascular endothelial growth factor receptor 2
KDR (VEGFR2) 989–1001 Y996 Vascular endothelial growth factor receptor 2
EPOR 361–373 Y368 Erythropoietin receptor
EPOR 419–431 Y426 Erythropoietin receptor
PECAM-1 706–718 Y713 Platelet endothelial cell adhesion molecule
PIK3R1 600–612 Y607 Phosphatidylinositol 3-kinase regulatory alpha subunit
EGFR 1190–1202 Y1197 Epidermal growth factor receptor
Cell adhesion, migration, and invasion
CALM1 95–107 Y100 Calmodulin
FES 706–718 Y713 Proto-oncogene tyrosine-protein kinase Fes/Fps
FER 707–719 Y714 Proto-oncogene tyrosine-protein kinase FER
LCK 387–399 Y394 Proto-oncogene tyrosine-protein kinase LCK
PXN 111–123 Y118 Paxillin
PXN 24–36 Y31/33 Paxillin
MST1R 1353–1365 Y1353, Y1360 Macrophage-stimulating protein receptor
CTTN 476–488 Y477, Y483 Src substrate protein p85
Cell survival and proliferation
CTNNB1 79–91 Y86 Beta-catenin
JAK1 1015–1027 Y1022, Y1023 Tyrosine-protein kinase JAK1
PDPK1 2–14 Y9 3-phosphoinositide dependent protein kinase 1
Other
CD247 116–128 Y123 T-cell surface glycoprotein CD3 zeta chain
CDK2 8–20 Y15, Y19 Cell division protein kinase 2
EPHA7 607–619 Y608, Y614 Ephrin type-A receptor 7
EPHB1 771–783 Y778 Ephrin type-B receptor 1
FRK 380–392 Y387 Tyrosine-protein kinase FRK
KRT6E 53–65 Y62 Keratin, type II cytoskeletal 6E
RET 1022–1034 Y1029 Proto-oncogene tyrosine-protein kinase receptor ret
a Substrate identities and common names are retrieved from UniProtKB/SwissProt [13]
b For each substrate, positions of the peptide sequence and the phosphorylation sites within the protein are indicated
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123might be technical variation among 96-well array plates,
the analytical strategy of including a tyrosine kinase
inhibitor was attempted, to enable direct comparison of
substrate phosphorylation in its presence and absence on
the same array plate, and possibly diminishing plate-to-
plate variation [8]. Sunitinib is thoroughly characterized in
vitro and in vivo for inhibiting tyrosine kinase signaling
related to tumor hypoxia [16]. Whether other tyrosine
kinase inhibitors might have worked equally well for nor-
malization of basal kinase activity data in the clinical set-
ting of interest (primary tumor signaling and DTC status),
is not known.
Using this strategy, phosphorylation of 31 kinase sub-
strates by tumor sample lysates was found to be signiﬁ-
cantly more strongly inhibited by sunitinib in the DTC-
negative patients than in patients with positive DTC status.
As tumors outgrow their blood supply or are otherwise
deprived of oxygen, adaptive responses to the resulting
hypoxic conditions are initiated [17]. In this context, the
transcription factors hypoxia-inducible factor types 1a and
2a have emerged as key regulators of a range of target
genes that induce angiogenesis, including genes encoding
platelet-derived growth factor, vascular endothelial growth
factor, and erythropoietin [1]. In this study, components of
hypoxia-driven signaling were identiﬁed in the 31-peptide
panel demonstrating differential response to sunitinib
inhibition in patients with negative and positive DTC sta-
tus, which included receptors for these ligands; ﬁve of six
PDGFR type b substrates, three of ten VEGFR substrates
(one VEGFR1 and two VEGFR2), and both EPOR sub-
strates on the array. The observed ex vivo regulation of
phosphorylation of these particular substrates was not
unexpected, since sunitinib has been noted to inhibit
several receptor tyrosine kinases, among which members
of the VEGFR and PDGFR families are predominant tar-
gets [16].
Signaling initiated by VEGFR and PDGFR is funda-
mentalfortheangiogenicresponse[1,5,6],whichcomprises
proliferation and invasion of endothelial cells and also for-
mation of pericyte coverage of vascular sprouts for stabil-
ization of the newly formed vessel walls. In this process,
PDGFR-dependent signaling is required for pericyte differ-
entiation directed by the tissue stroma [18]. It is tempting to
speculate that the strong ex vivo sunitinib inhibition of the
PDGFRarray substrate phosphorylation generated by tumor
samples from DTC-negative patients in this study reﬂects
high pericyte signaling activity of mature tumor vessel that
are less permeable for metastasizing tumor cells [19].
However, it cannot be ignored that among the 23 pep-
tides identiﬁed as angiogenesis-related in this study, ten
substrates were not correlated with the patients’ DTC sta-
tus, including seven of ten VEGFR substrates. Regulation
of tumor angiogenesis is a complex phenomenon. In
colorectal cancer, this complexity has recently been high-
lighted by the observation that anti-angiogenic therapy
(bevacizumab) that has proven efﬁcacious in metastatic
colorectal cancer, failed to meet the endpoint of prolonged
disease-free survival in randomized phase III trials in the
adjuvant setting [20, 21]. Interestingly, studies in experi-
mental models have indicated that mature pericytes protect
endothelial cells against VEGFR-directed therapies [22,
23]. The recent demonstration that tumor cells are able to
induce pericyte maturation of the neovasculature during
early formation of micrometastatic foci [24] might provide
one explanation for the lack of efﬁcacy of bevacizumab in
eradicating occult metastatic disease in colorectal cancer.
Fig. 3 Ex vivo sunitinib inhibition proﬁles from 23 angiogenesis-
related kinase substrates. Patient tumor samples along horizontal axis,
annotated by negative (-) or positive (?) status for disseminated
tumor cells to bone marrow, and phosphosubstrates along vertical
axis. Red corresponds to stronger and blue to weaker inhibition of
substrate phosphorylation. Left panel Substrate identities. For each
substrate, the position of phosphorylation sites within the protein is
indicated. (Color ﬁgure online)
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also included EPOR, the receptor for erythropoietin, which
is expressed in many non-hematopoietic tissues, including
endothelial cells and colorectal cancer [25], and has been
associated with angiogenic responses in experimental
tumor models [26]. Furthermore, this panel comprised
other candidate angiogenic regulators, such as PECAM-1
(platelet endothelial cell adhesion molecule-1), PIK3R1
(the PI3 K regulatory subunit a), and EGFR [27–29], as
well as the ephrin receptor types A7 and B1. Although
experimental studies suggest that several types of ephrin
receptors are activated in tumor vascularization [30], the
function of many subgroups is incompletely understood,
and in the current analyses, we therefore chose to exclude
ephrin receptors from the angiogenesis-related 23-peptide
panel.
The bone marrow compartment represents an important
site for hematogenous micrometastatic spread in breast and
prostate cancer, and clinical data has provided evidence for
an association between tumor cells detected in bone mar-
row at the time of tumor resection and postoperative met-
astatic relapse in these cancer types [14]. The presence of
systemically disseminated tumor cells has also been pro-
posed as biomarker of metastatic recurrence risk in colo-
rectal cancer [31]. In a study by Flatmark and co-workers
[11], the immunomagnetic selection method was used to
determine DTC status in 275 patients with primarily
resectable colorectal cancer, and recent update of the
clinical data shows that the presence of DTC was also
associated with poor long-term outcome in this patient
cohort [9]. In the present LARC-RRP study, using the same
method to examine bone marrow aspirates, absence of
DTC at the time of diagnosis was predictive of good short-
term metastasis-free survival after radical treatment of the
pelvic cavity. At the present stage of follow-up (median of
42 months), a non-signiﬁcant trend towards the same
association was found with overall survival. The overall
frequency of DTC-positive samples was higher in the
present study (60%) than in Flatmark’s study (17%), which
might be anticipated from the more locally advanced dis-
ease stage.
In summary, within a cohort of LARC patients, tumor
phenotypes deﬁned by tyrosine kinase activities that
appeared to correlate with weak ex vivo inhibition by
sunitinib, particularly related to angiogenic signaling, were
associated with early systemic dissemination. These
patients were also noted to have heightened risk of devel-
oping metastatic disease following the course of radical
treatment of the pelvic cavity. This novel strategy for
studying the functional tumor kinome in early metastatic
progression of rectal cancer may be used to improve our
understanding of the angiogenic response in metastasis.
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